Employment AgreementEmployment Agreement • June 13th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 13th, 2018 Company Industry JurisdictionThis Employment Agreement (the "Agreement") is made and entered into as of January 1, 2018 (the “Effective Date”), by and between David Moss, an individual (the "Executive"), and INmune Bio Inc., a Nevada corporation (the "Company").
INMUNE BIO, INC. Nonqualified Stock Option AgreementNonqualified Stock Option Agreement • June 13th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 13th, 2018 Company IndustryThis NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”), made and entered into on the ___ day of _____, 20___, to be effective as of such sate (the “Grant Date”), by and between ___________ (the “Participant”) and INmune Bio, Inc., a Nevada corporation (the “Company”), sets forth the terms and conditions of stock options issued to the Participant pursuant to the Company's 2017 Stock Incentive Plan (the “Plan”) and this Agreement, which options have been approved by the Company’s Board of Directors. Any capitalized terms used but not defined herein shall have the meaning prescribed in Annex A or in the Plan.
DATED 29th November 2017 - and - MATERIAL TRANSFER AND LICENCE AGREEMENTMaterial Transfer and License Agreement • June 13th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 13th, 2018 Company IndustryTHIS MATERIAL TRANSFER AGREEMENT together with its Schedules, the "Agreement" is made on 29 November 2017 , the "Effective Date", between
INMUNE BIO INC. 2017 STOCK INCENTIVE PLAN Incentive Stock Option AgreementIncentive Stock Option Agreement • June 13th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 13th, 2018 Company IndustryIn the event that the Company is not publicly traded, the Participant may exercise this Option on a cashless basis by using the last price per share at which at least $500,000 of shares or the conversion price of securities convertible into Common Stock was offered at and sold.
CONSULTING AGREEMENTConsulting Agreement • June 13th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledJune 13th, 2018 Company Industry JurisdictionTHIS AGREEMENT, dated as of May 16, 2018, between Immune Bio, Inc., with offices located at 1224 Prospect Street, Suite 150, La Jolla, California 92037, a Nevada Corporation (the “Company”), Pacific Seaboard Investments Ltd., having its principal place of business at Suite # 404-999 Canada Place, Vancouver, BC., V6C 3E2 a British Columbia corporation or its designee(s)(“CONSULTANT”).
Dear Dr. Lowdell, Consultancy agreementConsultancy Agreement • June 13th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJune 13th, 2018 Company IndustryWe are writing to confirm the terms of our agreement concerning the provision of your consultancy services to Inmune Bio International Ltd. (Client).